Moderna, a leader in mRNA medicine, developed one of the earliest COVID-19 vaccines, with Spikevax being its first commercial product. The company's mRNA platform enables the development of ...
Moderna (NASDAQ:MRNA) stock has surged 40.8% since the turn of the year. Some of this momentum can be traced to fears of new infectious disease outbreaks, which may represent a short-term supportive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback